Modulation of Cyclins, p53 and Mitogen-Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid

Despite the advances in cancer therapy and early detection, breast cancer remains a leading cause of cancer-related deaths among females worldwide. The aim of the current study was to investigate the antitumor activity of a novel compound, 4-(3,4,5-trimethoxyphenoxy)benzoic acid (TMPBA) and its mechanism of action, in breast cancer. Results indicated the relatively high sensitivity of human breast cancer cell-7 and MDA-468 cells towards TMPBA with IC50 values of 5.9 and 7.9 μM, respectively compared to hepatocarcinoma cell line Huh-7, hepatocarcinoma cell line HepG2, and cervical cancer cell line Hela cells. Mechanistically, TMPBA induced apoptotic cell death in MCF-7 cells as indicated by 4′,6-diamidino-2-phenylindole (DAPI) nuclear staining, cell cycle analysis and the activation of caspase-3. Western blot analysis revealed the ability of TMPBA to target pathways mediated by mitogen-activated protein (MAP) kinases, 5′ adenosine monophosphate-activated protein kinase (AMPK), and p53, of which the concerted action underlined its antitumor efficacy. In addition, TMPBA induced alteration of cyclin proteins’ expression and consequently modulated the cell cycle. Taken together, the current study underscores evidence that TMPBA induces apoptosis in breast cancer cells via the modulation of cyclins and p53 expression as well as the modulation of AMPK and mitogen-activated protein kinases (MAPK) signaling. These findings support TMPBA’s clinical promise as a potential candidate for breast cancer therapy.

[1]  M. Rateb,et al.  Synthesis, Anti‐Breast Cancer Activity, and Molecular Modeling of Some Benzothiazole and Benzoxazole Derivatives , 2013, Archiv der Pharmazie.

[2]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[3]  L. Kopelovich,et al.  Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. , 2013, Neoplasia.

[4]  L. Buja,et al.  Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. , 2000, Journal of molecular and cellular cardiology.

[5]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[6]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[7]  M. Lai,et al.  Endoplasmic Reticulum Stress Stimulates p53 Expression through NF-κB Activation , 2012, PloS one.

[8]  Chieh-Hsi Wu,et al.  OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways. , 2013, Toxicology and applied pharmacology.

[9]  D. Conte,et al.  Deregulation of cyclin E in breast cancer. , 1995, Oncogene.

[10]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[11]  K. Vousden,et al.  Coping with stress: multiple ways to activate p53 , 2007, Oncogene.

[12]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[13]  Y. Miki,et al.  The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. , 2010, Cancer science.

[14]  S. Kulp,et al.  Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. , 2010, Mini reviews in medicinal chemistry.

[15]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[16]  C. Shapiro,et al.  OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. , 2009, Carcinogenesis.

[17]  M. Pike,et al.  Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Furlong,et al.  YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity , 1996, Molecular and cellular biology.

[19]  I. Roninson,et al.  Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs , 1999, Oncogene.

[20]  H. Wu,et al.  NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. , 1994, The Journal of biological chemistry.

[21]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[22]  Y. Nakamura,et al.  The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.

[23]  D. Pipeleers,et al.  AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. , 2003, Journal of molecular endocrinology.

[24]  C. Isaacs,et al.  BRCA1/2 mutations and triple negative breast cancers. , 2010, Breast disease.

[25]  M. Rider,et al.  Sustained activation of AMP‐activated protein kinase induces c‐Jun N‐terminal kinase activation and apoptosis in liver cells , 2002, FEBS letters.

[26]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[27]  Clay C C Wang,et al.  Induction of Bcl-2 Expression by Hepatitis B Virus Pre-S2 Mutant Large Surface Protein Resistance to 5-Fluorouracil Treatment in Huh-7 Cells , 2011, PloS one.

[28]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[29]  Y. Kuo,et al.  Inhibitory Effect of Human Breast Cancer Cell Proliferation via p21-Mediated G1 Cell Cycle Arrest by Araliadiol Isolated from Aralia cordata Thunb. , 2010, Planta medica.

[30]  W. Willett,et al.  Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Shah,et al.  Cyclin-dependent kinases as targets for cancer therapy. , 2006, Cancer chemotherapy and biological response modifiers.

[32]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[33]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[34]  Navjot Shah,et al.  Water Extract of Ashwagandha Leaves Has Anticancer Activity: Identification of an Active Component and Its Mechanism of Action , 2013, PloS one.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[36]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[37]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[38]  M. Tsai,et al.  A novel indole-3-carbinol derivative inhibits the growth of human oral squamous cell carcinoma in vitro. , 2010, Oral oncology.

[39]  M. V. Heiden,et al.  Redox regulation of p53 during hypoxia , 2000, Oncogene.

[40]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[41]  J. Harper,et al.  Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.

[42]  A. Belal,et al.  Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues. , 2013, Bioorganic & medicinal chemistry letters.

[43]  T. Asano,et al.  Adenosine Monophosphate-Activated Protein Kinase Suppresses Vascular Smooth Muscle Cell Proliferation Through the Inhibition of Cell Cycle Progression , 2005, Circulation research.

[44]  S. Kulp,et al.  Targeting of the Akt-Nuclear Factor-κB Signaling Network by [1-(4-Chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma , 2009, Molecular Pharmacology.

[45]  Hong Yang,et al.  Shogaols at proapoptotic concentrations induce G2/M arrest and aberrant mitotic cell death associated with tubulin aggregation , 2011, Apoptosis.

[46]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.